GRI Bio Enhances Financial Stability Through Warrant Exercise
GRI Bio, Inc. (NASDAQ: GRI) has made a significant move to strengthen its financial position by announcing the exercise of certain existing warrants for its common stock. The biotechnology company specializes in developing Natural Killer T (NKT) cell modulators aimed at treating various diseases, including inflammatory, fibrotic, and autoimmune conditions.
Details of the Warrant Exercise
Under the new agreements, GRI Bio will exercise warrants allowing for the purchase of a total of 762,236 shares of its stock. Originally set at an exercise price of $14.30 per share, the new reduced price stands at just $1.00 per share. This strategic decision not only makes it more affordable for warrant holders but also paves the way for the conclusion of the offering, anticipated to close soon.
Role of H.C. Wainwright & Co.
H.C. Wainwright & Co. has taken on the important role of exclusive placement agent for this offering, ensuring that the transaction is managed efficiently. Their involvement underscores the importance of institutional support in driving GRI Bio’s financial maneuvering.
Issuance of New Warrants
As part of this arrangement, GRI Bio plans to issue new unregistered Series D-1 and Series D-2 warrants, each matching the previous number of shares—762,236. These new warrants will be immediately exercisable at the same price of $1.00 per share, with the Series D-1 warrants having a five-year term, while the Series D-2 warrants will last for eighteen months.
Projected Proceeds from the Offering
The gross proceeds from the exercise of these existing warrants are expected to be around $0.8 million, which will serve to enhance GRI Bio's working capital and support its ongoing corporate objectives.
Investment Opportunities and Regulatory Compliance
The new warrants will be offered through a private placement, aligning with the provisions outlined in the Securities Act of 1933. Notably, they will not be available for public sale unless an effective registration statement is in place. GRI Bio is committed to filing the necessary registration covering the resale of the shares obtainable via these warrants, which reflects the company’s dedication to transparency and compliance with applicable securities laws.
The Mission of GRI Bio
GRI Bio is focused on revolutionizing treatment approaches for inflammatory, fibrotic, and autoimmune diseases. Their innovative therapies are designed to target natural immune response mechanisms, particularly those involved in the activity of NKT cells. These special T cells serve a vital function in regulating inflammation and mediating responses to injury, thus playing a crucial role in disease management.
Innovative Pipeline of Treatments
The company’s lead program, GRI-0621, is highlighted as a promising therapeutic option for idiopathic pulmonary fibrosis. With the increasing recognition of this severe illness and the need for effective treatments, GRI Bio’s approach positions them as a key player in the biopharmaceutical landscape.
Future Directions for GRI Bio
As GRI Bio continues to develop its pipeline, the company envisions not only innovation in treatments but also a robust framework for financial health. With a library of over 500 proprietary compounds, GRI Bio is poised to fuel its advancements and maintain competitive momentum in the biotech industry.
Investor Contact:
For any inquiries, interested parties can reach out to the JTC Team, LLC, and connect with Jenene Thomas at (908) 824-0775 or via email at GRI@jtcir.com.
Frequently Asked Questions
What was announced by GRI Bio?
GRI Bio announced the exercise of existing warrants to purchase shares of its common stock at a reduced price to enhance its financial standing.
How many shares are involved in the warrant exercise?
The warrant exercise involves a total of 762,236 shares of common stock.
What is the new exercise price for the warrants?
The new exercise price for the warrants is set at $1.00 per share.
Who is acting as the placement agent for the offering?
H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering.
What is the primary aim of GRI Bio?
GRI Bio aims to innovate treatments for inflammatory, fibrotic, and autoimmune diseases by targeting the activity of NKT cells.
